IL192025A0 - Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions - Google Patents
Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditionsInfo
- Publication number
- IL192025A0 IL192025A0 IL192025A IL19202508A IL192025A0 IL 192025 A0 IL192025 A0 IL 192025A0 IL 192025 A IL192025 A IL 192025A IL 19202508 A IL19202508 A IL 19202508A IL 192025 A0 IL192025 A0 IL 192025A0
- Authority
- IL
- Israel
- Prior art keywords
- piperidineamides
- sulfamoyl
- prophylaxis
- obesity
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05111882 | 2005-12-09 | ||
| PCT/EP2006/069482 WO2007065948A1 (en) | 2005-12-09 | 2006-12-08 | Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL192025A0 true IL192025A0 (en) | 2008-12-29 |
Family
ID=36222433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL192025A IL192025A0 (en) | 2005-12-09 | 2008-06-10 | Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1960359A1 (ru) |
| JP (1) | JP2009518366A (ru) |
| KR (1) | KR20080074217A (ru) |
| CN (1) | CN101326166A (ru) |
| AU (1) | AU2006323952A1 (ru) |
| BR (1) | BRPI0619583A2 (ru) |
| CA (1) | CA2632719A1 (ru) |
| IL (1) | IL192025A0 (ru) |
| NO (1) | NO20083065L (ru) |
| RU (1) | RU2442773C2 (ru) |
| WO (1) | WO2007065948A1 (ru) |
| ZA (1) | ZA200804077B (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627221T3 (es) | 2006-12-28 | 2017-07-27 | Rigel Pharmaceuticals, Inc. | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso |
| NZ579229A (en) * | 2007-01-25 | 2011-07-29 | Verva Pharmaceuticals Ltd | Insulin sensitisers and methods of treatment |
| KR20140071518A (ko) * | 2009-05-01 | 2014-06-12 | 라퀄리아 파마 인코포레이티드 | Ｔｒｐｍ8 길항제로서의 설파모일 벤조산 유도체 |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN106546740B (zh) * | 2016-10-27 | 2019-04-09 | 暨南大学 | Ca2在鼻咽癌中的检测、治疗的应用 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL357678A1 (en) * | 2000-04-28 | 2004-07-26 | Sankyo Company, Limited | Ppargamma modulators |
| US6946476B2 (en) * | 2000-12-21 | 2005-09-20 | Schering Corporation | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
-
2006
- 2006-12-08 CA CA002632719A patent/CA2632719A1/en not_active Abandoned
- 2006-12-08 BR BRPI0619583-0A patent/BRPI0619583A2/pt not_active IP Right Cessation
- 2006-12-08 JP JP2008543846A patent/JP2009518366A/ja not_active Withdrawn
- 2006-12-08 RU RU2008127442/04A patent/RU2442773C2/ru not_active IP Right Cessation
- 2006-12-08 CN CNA2006800459849A patent/CN101326166A/zh active Pending
- 2006-12-08 WO PCT/EP2006/069482 patent/WO2007065948A1/en active Application Filing
- 2006-12-08 EP EP06830478A patent/EP1960359A1/en not_active Withdrawn
- 2006-12-08 KR KR1020087016422A patent/KR20080074217A/ko not_active Application Discontinuation
- 2006-12-08 AU AU2006323952A patent/AU2006323952A1/en not_active Abandoned
- 2006-12-08 ZA ZA200804077A patent/ZA200804077B/xx unknown
-
2008
- 2008-06-10 IL IL192025A patent/IL192025A0/en unknown
- 2008-07-08 NO NO20083065A patent/NO20083065L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009518366A (ja) | 2009-05-07 |
| WO2007065948A1 (en) | 2007-06-14 |
| BRPI0619583A2 (pt) | 2011-10-04 |
| RU2442773C2 (ru) | 2012-02-20 |
| CA2632719A1 (en) | 2007-06-14 |
| CN101326166A (zh) | 2008-12-17 |
| AU2006323952A1 (en) | 2007-06-14 |
| RU2008127442A (ru) | 2010-01-20 |
| KR20080074217A (ko) | 2008-08-12 |
| EP1960359A1 (en) | 2008-08-27 |
| NO20083065L (no) | 2008-09-04 |
| ZA200804077B (en) | 2009-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL192025A0 (en) | Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions | |
| IL191795A0 (en) | The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases | |
| PL1685834T3 (pl) | Zastosowanie kwasu pinolenowego do leczenia otyłości | |
| AP2007004245A0 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
| PL1981516T3 (pl) | Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom | |
| EP1853295A4 (en) | METHOD AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISEASES | |
| EP1940441A4 (en) | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS | |
| IL209848A0 (en) | Sclerostin and the inhibition of wnt signaling and bone formation | |
| IL181896A0 (en) | Methods and compositions for the treatment of hyperlipidemia | |
| IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
| IL188019A0 (en) | Novel peptides for use in the treatment of obesity | |
| EP1883416A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS RELATED TO INFLAMMATION | |
| ZA200707472B (en) | Diosmetin derivatives for the treatment and prevention of thrombotic pathologies | |
| IL196465A0 (en) | Compositions and methods for the treatment of mucositis | |
| GB0610350D0 (en) | prevention and/or treatment of neuodegenerative disorders | |
| IL184585A0 (en) | Prevention and treatment of thromboembolic disorders | |
| ZA200703087B (en) | Methods and compositions for the treatment of hyperlipidemia | |
| EP1996218A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
| IL191537A0 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| IL189009A0 (en) | Methods and compositions for the treatment of neuropathies and related disorders | |
| ZA200708033B (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
| EP1909809A4 (en) | METHOD AND COMPOSITION FOR TREATING DIABETES AND ITS COMPLICATIONS | |
| IL202523A0 (en) | Buspirone for the treatment of mausea and vomiting | |
| IL186021A0 (en) | Oxaprozin or closely related compound for the treatment and prevention of pruritus | |
| ZA200708278B (en) | Oxaprozin or closely related compound for the treatment and prevention of pruritus |